Miller S R, Bergmann D
SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406.
J Ind Microbiol. 1993 Jul;11(4):223-34. doi: 10.1007/BF01569595.
This article highlights biocontainment design considerations for biopharmaceutical manufacturing facilities. The major focus of this report is on industry's use and interpretation of the regulations with specific design recommendations for a Biosafety Level 2--Large-Scale physical containment level as described by the National Institutes of Health Guidelines.
本文重点介绍了生物制药生产设施的生物防护设计考量。本报告的主要重点是行业对法规的使用和解读，并针对美国国立卫生研究院指南中描述的生物安全2级——大规模实体防护水平提出了具体的设计建议。
